ReviewThe American journal of the medical sciences2016
Targeting the Mammalian Target of Rapamycin in Lung Cancer.
Review in The American journal of the medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy.Pharmaceutics · 2024Review
- Rapamycin-filgrastim combination therapy ameliorates portal hypertension-induced splenomegaly: Role of β actin and S100A9 proteins modulation.Iranian journal of basic medical sciences · 2022Article
- A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma.BioMed research international · 2022Article
- Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.Journal of cancer research and clinical oncology · 2021Article
- Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma.Frontiers in cell and developmental biology · 2021Article
- PaccMann: a web service for interpretable anticancer compound sensitivity prediction.Nucleic acids research · 2020Article
- Malignancy after lung transplantation.Annals of translational medicine · 2020Review
- EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer.Therapeutic advances in medical oncology · 2020Article
- Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.Oncology letters · 2019Article
- mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance.Journal of oncology · 2019Review
- Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment.International journal of nanomedicine · 2018Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer is the leading cause of cancer death worldwide. Despite advances in its prevention and management, the prognosis of patients with lung cancer remains poor. Therefore, much attention is being given to factors that contribute to the development of this disease, the mechanisms that drive oncogenesis and tumor progression and the search for novel targets that could lead to the development of more effective treatments. One cellular pathway implicated in lung cancer development and progression is that of the mammalian target of rapamycin. Studies involving human tissues have linked lung cancer with abnormalities in this pathway. Furthermore, studies in vitro and in vivo using animal models of lung cancer reveal that targeting this pathway might represent an effective means of treating this disease. As a result, there is significant effort invested in the development of drugs targeting mammalian target of rapamycin and related pathways in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.